查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1840585

虾病诊断市场（按技术、诊断方法、应用、最终用户和疾病类型）—2025-2032 年全球预测

Shrimp Disease Diagnostics Market by Technology, Diagnostic Method, Application, End User, Disease Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，虾病诊断市场将成长 8.948 亿美元，复合年增长率为 8.14%。

主要市场统计数据
基准年2024年 4.781亿美元
预计2025年 5.1754亿美元
预测年份：2032年 8.948亿美元
复合年增长率（%） 8.14%

提供关于诊断情报在保护虾类水产养殖健康、供应连续性和法规遵从性方面发挥的关键作用的权威指导

虾子病诊断是水产养殖韧性、公共卫生警戒和永续水产品供应链的交汇点。随着集约化虾类养殖规模不断扩大以满足全球蛋白质需求，虾类养殖业面临持续且不断演变的生物威胁，包括病毒、细菌、真菌和寄生虫。准确及时的诊断可能意味着局部控制和大规模生产损失之间的差异，同时也能影响抗菌药物管理、生物安全政策和贸易合规性。

诊断工作流程正从传统的组织病理学和基于培养的微生物学转向灵敏度更高、週转速度更快的分子和免疫学方法。实验室基础设施涵盖从集中式参考中心到现场检测能力的各种类型，相关人员正在寻求能够平衡速度、特异性、成本和现场稳定性的工具。同时，监管监督和买家对可追溯性的期望也要求检测方法必须经过验证，品质系统也必须透明。这些汇聚的力量正在再形成整个价值链的投资重点、营运实务和合作研究议程。

技术进步、数位整合和不断发展的监测如何改变整个虾类健康系统的诊断途径和决策

受技术日趋成熟、流行病学变化以及对营运韧性需求的推动，虾病诊断领域正在发生重大变化。聚合酵素链锁反应(PCR) 和次世代定序等分子方法已从专业实验室转向常规应用，从而提高了病原体检测的灵敏度。同时，恆温技术和快速免疫检测正在缩小实验室检验与养殖场决策之间的差距，缩短了养殖户在疫情急性爆发时的行动时间。

除了技术之外，样本追踪、云端基础分析和可互通资料标准的数位化平台的整合，正在改变监测资料的产生、汇总以及为政策和实践提供依据的方式。这些功能支持更细緻的疫情调查和纵向监测，同时结合环境和管理资料集，也能实现预测分析。此外，检测多路復用和自动化技术的进步，使实验室能够在不相应增加人员的情况下扩大通量，从而改变诊断服务提供者之间的服务交付模式和竞争动态。总而言之，这些转变正在推动整个诊断生态系统的研究投资、监管检验途径和商业性参与重点的重新调整。

关税变化对诊断供应链、采购週期以及虾类健康管理先进检测能力的实际影响

诸如关税调整之类的政策变化将对整个虾病诊断生态系统产生实际的连锁反应，影响试剂采购、设备采购和服务交付的经济效益。关税上调会增加进口耗材和资本设备的成本，这将迫使实验室和诊断供应商重新评估其供应链，并优先考虑本地和具有关税抵御能力的供应商。虽然这种转变可以鼓励供应商多元化以及试剂和基本设备的国内生产，但也可能延长依赖复杂全球供应链的专业平台的采购週期。

关税调整导致的采购波动通常会促使诊断服务供应商重新评估定价、合约条款和库存策略，以保持其水产养殖客户检测的连续性。同时，依赖国际试剂和跨国检体交换的研究合作可能会遭遇行政摩擦，导致其更加重视国内验证研究和替代检测方法。对于水产养殖生产者而言，间接影响可能包括高端诊断工具取得管道的变化以及新实验室能力投入使用的前置作业时间延长，从而可能改变疫情应对时间表和技术创新的采用速度。

将技术、诊断方式、应用、最终用户和疾病类别与可行的采用选择联繫起来的多维细分观点

了解细分领域可为评估诊断能力和机会的交会点提供实用视角。从技术角度来看，该领域涵盖免疫检测和检测法恒温环型核酸扩增相符，次世代定序仪酵素结合免疫吸附试验 (ELISA) 与侧流免疫测定和蛋白质印迹法并列为抗体和抗原检测的不同选择。应用导向的细分涵盖从常规监测和筛检到监测和疫情调查等各种用例，每个用例都需要独特的效能特征和操作工作流程。最终用户类别进一步细化了采用模式，学术和研究机构专注于方法开发和验证，诊断实验室优先考虑服务交付和吞吐量，水产养殖场优先考虑与农场管理相结合的快速、可操作的结果。最后，细菌、真菌、寄生虫和病毒疾病类型的细分决定了检测的特异性和采样策略，因为这些病原体的生物学和传播动力学需要不同的诊断途径。

这些环节的相互作用决定了投资、培训和品质保证的重点，从而实现可靠的诊断。例如，选择多重PCR还是单靶定量PCR，将取决于生产系统中病毒病原体的流行程度和共存情况；而选择实验室ELISA还是侧流检测装置，则需要权衡灵敏度和养殖场易用性。将技术性能与特定应用和最终用户相匹配的研究和检验工作，将提升诊断产品和服务在虾类健康领域的转换价值。

生产量、法律规范和检测能力的地理差异如何影响诊断重点和协作监测结果

区域动态反映了生产强度、法规环境和研究能力，决定了诊断需求、投资重点和协力网路。在美洲，成熟的水产养殖区将日益增长的可追溯性需求与不断扩大的诊断服务网络结合。这种环境促进了对实验室自动化、标准化通讯协定和官民合作关係关係的投资，从而加强了监测并支持了出口市场需求。同时，欧洲、中东和非洲地区的管理体制和基础设施成熟度各不相同，在这些地区，监管协调和统一的检验标准对于实现跨境贸易和协调一致的疫情应对至关重要。

亚太地区仍然是全球虾类养殖的中心，因此也是疾病控制挑战的集中地。该地区高密度的养殖系统、多样化的病原体压力以及蓬勃发展的诊断供应商群体，正在推动分子平台和实用的现场检测方法的快速应用。在该地区，对培训、分散检测能力和本地化检测验证的投资尤其重要，因为它们能够实现快速的养殖决策，并将诊断方法纳入生物安全通讯协定。在所有地区，跨境知识交流、统一的数据标准和合作研究联盟将提高监测的有效性，并支持更具韧性的疾病应对策略。

诊断提供者之间的策略行动和伙伴关係模式将决定整个产业的创新速度、检验的严谨性和服务的扩充性

活跃于虾病诊断领域的公司和机构之间的竞争反映了不同的策略模式。一些公司优先考虑平台技术和全球分销，其他公司则强调服务产品和区域化的「样本到答案」解决方案，而新参与企业则专注于可携式恆温分析和专业测序等利基创新。试剂製造商、设备供应商和诊断实验室之间的策略伙伴关係有助于加快检验的工作流程的上市时间，并分担监管提交和现场检验的负担。投资于可扩展生产、强大的品质系统和可互通数据解决方案的公司可以支援更大规模的监测项目，并与可追溯性倡议相结合。

此外，研发途径越来越依赖与学术机构的合作，共同开发检测方法，并在相关的现场条件下进行严格的验证。此外，将检测与咨询和生物安全咨询相结合的服务型经营模式能够创造经常性收益来源并深化客户关係。为了保持竞争力，企业必须在产品创新投资与验证、法规遵循和客户教育方面的承诺之间取得平衡，同时也要考虑如何根据不同的区域采购能力和采购环境调整定价和分销策略。

诊断提供者和水产养殖领导者可以采取的具体策略步骤，以增强韧性、加速采用并使创新与营运需求保持一致

产业领导者应优先建构具有韧性的供应链，实现试剂和设备来源多元化，同时投资区域缓衝库存和製造外包，以降低贸易政策衝击的影响。加强与区域实验室和研究机构的合作，将有助于快速检验替代检测方法，并支援旨在提升熟练技术人员能力的培训计画。领导者还应加快部署用于样本追踪、结果整合和分析的数位基础设施，将分散的诊断数据转化为可供生产商和监管机构操作的情报。

在产品方面，企业应推行模组化检测设计，以便快速重新配置新的或共存的病原体，并检验适合现场使用的检测方案，以维持实验室级性能。与水产养殖生产商的策略合作有助于将诊断开发与营运工作流程相结合，并启动先导计画，以证明疾病预防方面的投资回报。最后，透明的品质保证流程、统一的验证通讯协定以及参与实验室间比对研究，可以增强买家信心，支持监管机构的认可，并促进先进诊断方法的广泛应用。

该分析以严格的混合方法研究框架为基础，结合了专家咨询、技术性能审查和三段论证据综合。

这些见解背后的调查方法结合了系统性文献综述、结构化访谈和技术绩效评估，以确保观点的平衡和主导。定性研究部分包括咨询诊断实验室主任、水产养殖卫生官员、设备供应商和监管顾问，以了解区域营运限制和采用驱动因素。补充性二次分析整合了同行评审研究、技术白皮书和公开的监测报告，以提供技术能力和疾病流行情况的图像。

技术评估包括交叉比较检测参数，例如灵敏度、特异性、结果产生时间和现场适用性，以及考虑目标地区的监管途径和验证要求。数据合成包括协调不同的资讯来源并应用三角测量技术来识别稳健的模式，品质保证步骤包括与领先的断言专家进行交叉验证。该研究认识到快速发展的病原体模式所固有的局限性，并建议随着新的检验数据和监管格局的发展定期更新。

简明摘要强调了有效诊断、跨部门合作和能力建设对于实现虾类健康可持续改善的重要性。

诊断技术是永续虾类生产的战略关键，它能够更有针对性地应对疾病威胁，并支持生物安全、贸易和消费者信心。分子平台、快速免疫检测和数位分析的整合扩展了生产者、实验室和监管机构可用的实际选择，而不断变化的区域动态和政策也持续影响技术的取得和采用途径。将技术投资与检验的性能、营运可行性和监管预期相结合的相关人员将最有能力减轻疫情的影响并提高长期的抵御能力。

公司必须提供经过验证且适用的检测方法，实验室必须保持严格的品质标准，生产商必须将诊断方法纳入其日常管理和生物安全实践。对协作管治、统一标准和能力建设的投资将加速将诊断资讯转化为对虾子健康和生产永续性的实际改善。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 基于 CRISPR 的照护现场诊断检测方法日益普及，可快速检测虾病原体
  • 将人工智慧预测分析与虾场遥测技术结合，以预警疾病爆发
  • 开发一种可同时检测多种虾毒和细菌性疾病的多重PCR检测方法
  • 携带式等温扩增装置越来越多地用于养殖场虾病的现场监测
  • 实施次世代定序平台，实施全面的虾子病原体监测计划
  • 推出利用奈米技术快速辨识虾病原体的手持式生物感测器晶片
  • 扩展物联网连接的水质感测器和疾病诊断工具，以优化虾子的健康管理

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 虾子病诊断市场（依技术）

  • 酵素结合免疫吸附试验
  • 环介导等温扩增
  • 次世代定序
  • 聚合酵素链锁反应
    • 多重PCR
    • 定量PCR
    • 逆转录PCR

9. 虾子病诊断市场（依诊断方法）

  • 组织病理学诊断
  • 免疫学诊断
    • 酵素结合免疫吸附试验
    • 侧流免疫检测
    • 蛋白质印迹法
  • 微生物诊断
  • 分子诊断

第十章虾病诊断市场的应用

  • 监控
  • 疫情调查
  • 调查
  • 筛检

第 11 章。虾子病诊断市场（按最终用户）

  • 学术机构
  • 水产养殖场
  • 诊断实验室
  • 研究机构

第 12 章虾病诊断市场（依疾病类型）

  • 细菌性疾病
  • 真菌病
  • 寄生虫病
  • 病毒性疾病

第十三章虾病诊断市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章虾病诊断市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 虾子病诊断市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Thermo Fisher Scientific, Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • PerkinElmer, Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Ceva Sante Animale SA
Product Code: MRR-03023C19E52A

The Shrimp Disease Diagnostics Market is projected to grow by USD 894.80 million at a CAGR of 8.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 478.10 million
Estimated Year [2025] USD 517.54 million
Forecast Year [2032] USD 894.80 million
CAGR (%) 8.14%

An authoritative orientation to the critical role of diagnostic intelligence in safeguarding shrimp aquaculture health, supply continuity, and regulatory compliance

Shrimp disease diagnostics sits at the intersection of aquaculture resilience, public health vigilance, and sustainable seafood supply chains. As intensive shrimp farming expands to meet global protein demand, the industry confronts a persistent and evolving set of biological threats driven by viral, bacterial, fungal, and parasitic agents. Accurate and timely diagnosis determines the difference between localized containment and large-scale production losses, while also shaping antimicrobial stewardship, biosecurity policies, and trade compliance.

Diagnostic workflows have diversified from traditional histopathology and culture-based microbiology toward molecular and immunological approaches that deliver greater sensitivity and faster turnaround. Laboratory infrastructure now ranges from centralized reference centers to on-site testing capabilities, and stakeholders require tools that balance speed, specificity, cost, and field robustness. At the same time, regulatory scrutiny and buyer expectations for traceability demand validated assays and transparent quality systems. These convergent forces are reshaping investment priorities, operational practices, and collaborative research agendas across the value chain.

How technological advances, digital integration, and evolving surveillance practices are reshaping diagnostic pathways and decision-making across shrimp health systems

The diagnostic landscape for shrimp diseases is undergoing transformative shifts driven by technological maturation, shifting epidemiology, and the imperative for operational resilience. Molecular modalities such as polymerase chain reaction variants and next-generation sequencing have moved from specialty labs into routine use, enabling pathogen detection with higher sensitivity and enabling strain-level discrimination that informs targeted interventions. Concurrently, isothermal technologies and rapid immunoassays are closing the gap between laboratory validation and on-farm decision-making, reducing time-to-action for producers facing acute outbreaks.

Beyond technology, integration of digital platforms for sample tracking, cloud-based analytics, and interoperable data standards is changing how surveillance data is generated, aggregated, and translated into policy and practice. These capabilities support more nuanced outbreak investigations and longitudinal monitoring, while also enabling predictive analytics when paired with environmental and management datasets. Moreover, advancements in assay multiplexing and automation are enabling laboratories to scale throughput without proportionally increasing labor, which in turn alters service delivery models and the competitive dynamics among diagnostic providers. Taken together, these shifts recalibrate priorities for research investment, regulatory validation pathways, and commercial engagement across the diagnostic ecosystem.

Real-world repercussions of tariff shifts on diagnostic supply chains, procurement cycles, and access to advanced testing capabilities in shrimp health management

Policy changes such as revised tariff regimes have practical ripple effects across the shrimp disease diagnostics ecosystem, influencing reagent sourcing, instrument procurement, and the economics of service delivery. When tariffs increase costs for imported consumables and capital equipment, laboratories and diagnostic suppliers reassess supply chains and prioritize vendors with local or tariff-resilient footprints. This reorientation can accelerate supplier diversification and incentivize domestic production of reagents and basic instrumentation, but it may also lengthen procurement cycles for specialized platforms that rely on complex global supply chains.

Procurement volatility caused by tariff adjustments often prompts diagnostic service providers to re-evaluate pricing, contract terms, and inventory strategies to preserve continuity of testing for aquaculture clients. In parallel, research collaborations that depend on internationally sourced reagents or cross-border specimen exchange may encounter administrative friction, prompting greater emphasis on in-country validation studies and alternative assay formats. For aquaculture operators, the indirect consequences include shifts in access to high-end diagnostics and longer lead times for commissioning new laboratory capabilities, which can alter outbreak response timelines and the pace at which innovation is adopted.

A multidimensional segmentation perspective that links technologies, diagnostic modalities, applications, end users, and disease classes to practical adoption choices

Understanding segmentation provides a pragmatic lens to evaluate where diagnostic capabilities and commercial opportunities converge. When the technology axis is examined, the field spans conventional immunoassays such as enzyme linked immunosorbent assay alongside nucleic acid amplification methods including loop mediated isothermal amplification and polymerase chain reaction variants, with next generation sequencing offering comprehensive genomic insight; within polymerase chain reaction approaches practitioners distinguish multiplex PCR, quantitative PCR, and reverse transcription PCR according to the needs for throughput, quantitation, and RNA pathogen detection. Diagnostic method distinctions complement this view, encompassing histopathological diagnostics and microbiological culturing alongside molecular diagnostics and immunological approaches where enzyme linked immunosorbent assay sits with lateral flow immunoassay and western blot as differing options for antibody or antigen detection. Application-oriented segmentation frames use cases ranging from routine monitoring and screening to research and outbreak investigation, each demanding specific performance characteristics and operational workflows. End user categories further refine adoption patterns, with academic institutions and research institutes focusing on method development and validation, diagnostic laboratories concentrating on service delivery and throughput, and aquaculture farms prioritizing rapid, actionable results that integrate with on-farm management. Finally, disease type segmentation-spanning bacterial, fungal, parasitic, and viral diseases-dictates assay specificity and sampling strategies, since the biological behaviors and transmission dynamics of these agent classes require distinct diagnostic pathways.

These interlocking segment dimensions drive where investment, training, and quality assurance must be applied to realize reliable diagnostics. For example, decisions around adopting multiplex PCR versus single-target quantitative PCR are informed by the prevalence and co-occurrence of viral pathogens in a production system, while the choice between laboratory-based ELISA and lateral flow devices reflects trade-offs between sensitivity and on-farm usability. Research and validation efforts that align technology performance to specific applications and end users enhance the translational value of diagnostic products and services across the shrimp health landscape.

How geographic differences in production intensity, regulatory frameworks, and laboratory capacity determine diagnostic priorities and collaborative surveillance outcomes

Regional dynamics shape diagnostic needs, investment priorities, and collaborative networks in ways that reflect production intensity, regulatory environments, and research capacity. In the Americas, established aquaculture regions combine growing demand for traceability with expanding diagnostic service networks; this setting favors investments in laboratory automation, standardized protocols, and public-private partnerships that strengthen surveillance and support export market requirements. Meanwhile, Europe, Middle East & Africa presents a mosaic of regulatory regimes and infrastructure maturity, where regulatory alignment and harmonized validation standards are critical to enabling cross-border trade and coordinated outbreak responses, and where capacity-building initiatives often prioritize establishing accredited reference laboratories and harmonized reporting frameworks.

The Asia-Pacific region remains central to global shrimp production and therefore concentrates a large share of disease management challenges; here, high-density farming systems, diverse pathogen pressures, and a thriving diagnostics supplier base drive rapid uptake of both molecular platforms and pragmatic field-ready assays. Investment in training, decentralized testing capabilities, and localized assay validation are particularly important in this region, as they enable faster on-farm decisions and stronger integration of diagnostics into biosecurity protocols. Across all regions, cross-border knowledge exchange, harmonized data standards, and collaborative research consortia amplify the effectiveness of surveillance efforts and support more resilient disease response strategies.

Strategic behaviors and partnership models among diagnostics providers that determine innovation velocity, validation rigor, and service scalability across the industry

Competitive dynamics among firms and institutions active in shrimp disease diagnostics reflect divergent strategic models: some prioritize platform technologies and global distribution, others emphasize service provision and localized sample-to-answer solutions, while emerging entrants focus on niche innovations such as portable isothermal assays or specialized sequencing analytics. Strategic partnerships between reagent manufacturers, instrument suppliers, and diagnostic laboratories accelerate time to market for validated workflows and help distribute the burden of regulatory submission and field validation. Companies that invest in scalable manufacturing, robust quality systems, and interoperable data solutions position themselves to support larger surveillance programs and integrate with traceability initiatives.

Innovation pathways also increasingly rely on alliances with academic and research institutions to co-develop assays and to conduct rigorous validation under relevant field conditions. Furthermore, service-based business models that combine testing with advisory and biosecurity consulting create recurring revenue streams and deepen customer relationships. To remain competitive, organizations must balance investments in product innovation with commitments to validation, regulatory compliance, and customer education, while also considering how to adapt pricing and distribution strategies to diverse regional purchasing capacities and procurement environments.

Concrete strategic steps that diagnostic providers and aquaculture leaders can adopt to strengthen resilience, accelerate adoption, and align innovations with operational needs

Industry leaders should prioritize creating resilient supply chains by diversifying reagent and instrument sourcing while investing in localized buffer stocks and contract manufacturing arrangements to reduce exposure to trade policy shocks. Strengthening ties with regional laboratories and research institutions enables faster validation of alternative assays and supports training programs that expand skilled technical workforce capacity. Leaders should also accelerate the adoption of digital infrastructure for sample tracking, result integration, and analytics to convert dispersed diagnostic data into actionable intelligence for producers and regulators.

On the product side, companies should pursue modular assay designs that allow rapid reconfiguration for new or co-circulating pathogens, and they should validate field-suitable formats that preserve laboratory-level performance. Strategic collaborations with aquaculture producers can help align diagnostic development with operational workflows and create pilot projects that demonstrate return-on-investment in disease prevention. Finally, transparent quality assurance processes, harmonized validation protocols, and participation in inter-laboratory comparison studies will build trust among buyers, support regulatory acceptance, and facilitate wider adoption of advanced diagnostics.

A rigorous mixed-methods research framework blending expert consultations, technical performance review, and triangulated evidence synthesis to underpin the analysis

The research approach underlying these insights combined systematic literature review, structured interviews, and technology performance assessments to ensure a balanced and evidence-driven perspective. The qualitative component included consultations with diagnostic laboratory directors, aquaculture health managers, instrument suppliers, and regulatory advisors to capture operational constraints and adoption drivers across geographies. Complementary secondary analysis synthesized peer-reviewed studies, technical white papers, and publicly available surveillance reports to characterize technology capabilities and disease prevalence contexts.

Technical evaluation involved cross-comparison of assay parameters such as sensitivity, specificity, time-to-result, and field suitability, as well as consideration of regulatory pathways and validation requirements in target regions. Data synthesis applied triangulation methods to reconcile differing sources and identify robust patterns, while quality assurance steps included cross-validation of key claims with subject-matter experts. The study acknowledges limitations inherent to rapidly evolving pathogen landscapes and recommends periodic updates as new validation data and regulatory developments emerge.

A concise synthesis underscoring the centrality of validated diagnostics, cross-sector collaboration, and capacity-building for durable shrimp health outcomes

Diagnostics constitute a strategic linchpin for sustainable shrimp production, enabling more precise responses to disease threats and supporting biosecurity, trade, and consumer confidence. The convergence of molecular platforms, rapid immunoassays, and digital analytics is expanding the practical options available to producers, laboratories, and regulators, while regional dynamics and policy shifts continue to shape access and adoption pathways. Stakeholders who align technology investments with validated performance, operational feasibility, and regulatory expectations will be best positioned to reduce outbreak impacts and improve long-term resilience.

Looking ahead, success will depend on coordinated efforts across the value chain: companies must deliver validated, fit-for-purpose assays; laboratories must uphold rigorous quality standards; and producers must integrate diagnostics into routine management and biosecurity practices. Collaborative governance, harmonized standards, and investments in capacity-building will accelerate the translation of diagnostic intelligence into on-the-ground improvements in shrimp health and production sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of CRISPR-based point-of-care diagnostic assays for shrimp pathogens enabling faster detection
  • 5.2. Integration of AI-powered predictive analytics with shrimp farm telemetry for early disease outbreak alerts
  • 5.3. Development of multiplex PCR assays for simultaneous detection of multiple shrimp viral and bacterial diseases
  • 5.4. Growing use of portable isothermal amplification devices for on-site shrimp disease monitoring at farms
  • 5.5. Implementation of next generation sequencing platforms for comprehensive shrimp pathogen surveillance programs
  • 5.6. Emergence of handheld biosensor chips leveraging nanotechnology for rapid shrimp pathogen identification
  • 5.7. Expansion of IoT-connected water quality sensors coupled with disease diagnostic tools to optimize shrimp health management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Shrimp Disease Diagnostics Market, by Technology

  • 8.1. Enzyme Linked Immunosorbent Assay
  • 8.2. Loop Mediated Isothermal Amplification
  • 8.3. Next Generation Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Multiplex PCR
    • 8.4.2. Quantitative PCR
    • 8.4.3. Reverse Transcription PCR

9. Shrimp Disease Diagnostics Market, by Diagnostic Method

  • 9.1. Histopathological Diagnostics
  • 9.2. Immunological Diagnostics
    • 9.2.1. Enzyme Linked Immunosorbent Assay
    • 9.2.2. Lateral Flow Immunoassay
    • 9.2.3. Western Blot
  • 9.3. Microbiological Diagnostics
  • 9.4. Molecular Diagnostics

10. Shrimp Disease Diagnostics Market, by Application

  • 10.1. Monitoring
  • 10.2. Outbreak Investigation
  • 10.3. Research
  • 10.4. Screening

11. Shrimp Disease Diagnostics Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Aquaculture Farms
  • 11.3. Diagnostic Laboratories
  • 11.4. Research Institutes

12. Shrimp Disease Diagnostics Market, by Disease Type

  • 12.1. Bacterial Diseases
  • 12.2. Fungal Diseases
  • 12.3. Parasitic Diseases
  • 12.4. Viral Diseases

13. Shrimp Disease Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Shrimp Disease Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Shrimp Disease Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific, Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. F. Hoffmann-La Roche Ltd
    • 16.3.4. Abbott Laboratories
    • 16.3.5. PerkinElmer, Inc.
    • 16.3.6. QIAGEN N.V.
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. Zoetis Inc.
    • 16.3.9. Merck & Co., Inc.
    • 16.3.10. Ceva Sante Animale S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SHRIMP DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SHRIMP DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SHRIMP DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOG